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ABSTRACT 
Cervical cancer, a malignant cancer is leading second most cancer found in women. Telmisartan has 3000 times more affinity toward 
angiotensin II receptor type 1 (AT1) receptor than AT2 and inhibited neovascularization by down-regulating VEGF acting on endothelial cells 
with antagonized activity of Angiotensin II. Despite well-known therapeutic potential of telmisartan in malignant cancer, poor physicochemical 
properties and pharmacokinetic propertiesincluding meageraqueous solubility (0.078 mg/mL), low oral bioavailability (45-58%), and erratic 
biodistribution not only limit the therapeutic potential of telmisartan in treatment of malignant cancer but also appeal for development of 
dosage form with enhanced oral bioavailability.Telmisartan encapsulated stearic acid nanostructured solid lipid particles were developed by 
solvent diffusion method. On applying of box behnken design with three factors and three levels, 17 different formulations were yieldedand 
prepared with Response of particle size (Y1) and percentage drug entrapment (Y2) for 17 formulations were evaluated. The IC50 value of 
optimized telmisartan loaded lipid nanoparticle and market preparation, indicated telmisartan loaded solid lipid nanoparticleexpressed lower 
IC50 value of 30.28 μM with significant anticancer activity against HeLa cancer cell line in comparison to higher IC50 value 58.69 μM of market 
preparation. In conclusion, telmisartan loaded solid lipid nanoparticles may be a promising drug delivery systems for cervical cancer.  
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INTRODUCTION 
Cervical cancer, a malignant cancer is leading second most 
cancer found in women, affects approximately 50000 million 
women and accountable for 200000 million deaths per year 
in developing countries including India. It is assumed that by 
2030 rate of death via cervical cancer increases by 30% in 
low and middle developing with 73000 new cases in India.  
Among all ARBs, telmisartan has been preclinically tested in 
the treatment of several cancers.  Telmisartan has 3000 
times more affinity toward angiotensin II receptor type 
1 (AT1) receptor than AT21and inhibited neovascularization 
by down-regulating VEGF acting on endothelial cellswith 
antagonized activity of Angiotensin II.  
Despite well-known therapeutic potential of telmisartan in 
malignant cancer, poor physicochemical properties and 
pharmacokinetic propertiesincluding meageraqueous 
solubility (0.078 mg/mL), low oral bioavailability (45-58%), 
and erratic biodistribution not only limit the therapeutic 
potential of telmisartan in treatment of malignant cancer but 
also appeal for development of dosage form with enhanced 
oral bioavailability.2-4 
Cytotoxic chemotherapeutic has been administered through 
various routes in the treatment of cervical cancer however 
oral route is the most prevalent route of administration of 
the drug in term of cost effective and patient compliance. 
However, the physiological barrier of GIT tract, structural 
geometry and characteristic propertiesof cervical tumors 
presentsvarious significant challenges including poor 
absorption, low oral bioavailability, multidrug resistance, 
less specificity, systemic toxicity, and low therapeutic 
efficacytowards the oral administration of 
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chemotherapeutic5.Therefore, need the development of 
carrier system or drug delivery technologies which can 
reduce toxicity, multiple drug resistance andaugment 
absorption, drug concentration at a particular siteand 
bioavailability of drug therapeutic molecule.6 
Recent finding indicated that among all carrier system solid 
lipid nanoparticles, physically engineering particles with a 
size range of 1-100 nm, are considered a good alternative to 
conventional chemotherapy because it canimprove drug 
bioavailability and decrease the toxicityof drug therapeutic 
molecule7.Moreover, its characteristic properties including 
high volume to surface area ratio, augment absorption, 
enhanced dissolution, matrix encapsulation and deliver 
highly lipophilic drug pose them a good candidate for 
delivery of cancer chemotherapeutics via the oral route of 
administration in cervical cancer treatment.  
In this context, solid lipid nanoparticles have been 
extensively investigated for delivery of cancer 
chemotherapeutics through oral route of administration. As 
reported in the literature, Solid lipid nanoparticle can easily 
transport a thorough gut wall to the systemic circulation. 
Small size and lipid matrix of solid lipid nanoparticle 
facilitateabsorption by intestine either as a particulate 
matter via M cells of payerpatches with a paracellular 
pathway8 or as a lipase mediated mixed micelles through the 
gut wall and the encapsulated drug was further transferred 
to the systemic circulation through intestinal lymphatics via 
thoracic lymph duct. In addition, to augment the absorption 
of the drug, surfactant of solid lipid nanoparticle leads 
inhibition of Pgp-mediated efflux of the drug. 
Therefore, the aim of present investigation was to develop 
and optimize telmisartan loaded stearic acid containing solid 
lipid nanoparticle using solvent diffusion method by 
employing box behnken design. The tailored formulation was 
subjected to several in vitro characterization technique 
including particle size, percentage drug entrapment, 
percentage drug loading, in vitro drug release and kinetics, 
Cell cytotoxicity studies, etc… 
MATERIALS AND METHODS 
Materials 
Telmisartan (TEL) was a kind gift sample from Swiss Garnier 
Life Sciences, Indi, Stearicacid was obtained from Thomas 
Baker, India. All other chemicals used were of the highest 
analyticalgrade. 
Development of telmisartan loaded nanostructure solid 
lipid particles 
Telmisartan encapsulated stearic acid nanostructured solid 
lipid particles were developed by solvent diffusion method1 
in an aqueous surfactant solution. In brief,an appropriate 
weighed amount of stearic acid and 40mg of telmisartan was 
completely solubilized into an equivolume mixture of ethyl 
alcohol (6ml) and acetone (6ml). Furthermore, the resulting 
organic phase immediately dispersed into 100ml surfactant-
containing aqueous phase at 70°C under continuous stirring 
by employing a hot plate magnetic stirrer for 30min. to 
complete evaporation of the organic solvent, Finally, the 
obtained nanodispersion was cooled at room temperature 
and subjected to freeze-drying to obtain a free-flowing 
powder of telmisartan loaded nanostructured solid lipid 
particles (TEL-SLN).  
Experimental design for optimization 
Currently, an approach comprising mathematical models 
based on statistics has been widely used for optimization and 
validation of process and formulation parameters for 
preparation of TEL-SLN. In this work, a three-factor three-
level Box–Behnken experimental design was employed to 
optimized, validate and to elucidate the influence of 
independent parameters including drug lipid ration, the 
concentration of surfactant and stirring rpm and their 
interaction effect over the properties including particle size, 
Percentage drug entrapment and PI of telmisartan loaded 
solid lipid nanoparticle.Each independent parameter was 
studied at three different levels including low level (-1), 
medium level (0) and high level (+1), respectively as 
illustrated in Table.1.On applying of box behnken design9 of 
experiment software a total 17 run were generated including 
12 axial points and one central point with five replicates as 
displayed in Table 2 for which quadratic polynomial 
equation was generated is as given: 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 =  𝛽0 + 𝛽1. 𝑋1 − 𝛽2. 𝑋2−𝛽3. 𝑋3 + 𝛽4 . 𝑋1. 𝑋2 −𝛽5   𝑋1. 𝑋3 + 𝛽6. 𝑋2. 𝑋3 +  𝛽7. 𝑋12 + 𝛽8. 𝑋22 + 𝛽9.𝑋32 
Response was the measurement of predicated value of each 
dependent variable, β0 is intercept, β1, β2, β3, are linear coefficient, β4, β5, β6 are interaction coefficient, β7, β8, β9 are 
quadratic coefficient and X1, X2, X3 are independent variable 
was selected on the basis of initial screening of parameters. 
All 17 formulations were prepared as per the independent 
variable selected in table no. and data was analyzed by 
employing design expert 7.0. The selection of best fit model 
was done by comparing various statistical parameters 
including p value, adjusted regression coefficient (R2), 
predicated regression coefficient (R2), and lack of fit, 
etc.ANOVA was employed to assess the significant value of 
each response parameter. The relationship between 
independent factor and response was expressed using 3D 
surface plot and the final formulation was be optimized with 
the maximum value of percentage drug entrapment with a 
minimum value of particle size. 
In vitro characterization of telmisartan loaded 
nanostructured solid lipid particles 
Percentage of drug encapsulation efficiency and drug 
loading 
The percentage drug encapsulation efficiency and drug 
loading capacity of TEL-SLN18was determined using the 
ultracentrifuge filtration method. This method comprising 
the determination of free drug available over the surface of 
solid lipid nanoparticle by dispersing separately 10mg 
weighed quantity of freeze-dried telmisartan loaded solid 
lipid nanoparticle of each formulation in 10ml of 0.1N NaoH. 
TEL-SLN18 dispersion was ultra-centrifuged at 50000 rpm 
for 4 hr. at 4°C and consequently, the obtained supernatant 
was filtered off by employing 0.22µm membrane filter. The 
concentration of telmisartan in the supernatant was 
determined through UV spectrophotometer at 𝜆max 298 nm. 
All analysis was carried out in triplicate (n=3). 
Percentage drug encapsulation efficiency and drug loaded 
capacity was determined according to the equation are as 
given below. % 𝐷𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = Total amount of drug added − Amount of drug extracted in the supernatent Total amount of drug added× 100 
 % 𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦= Amount of drug encapsulated Total amount of solid lipid nanoparticle× 100 
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Particle size and Zeta Potential 
Average particle size, size distribution, and zeta potential of 
optimized tailoredTEL-SLN18 formulations were determined 
by employing Malvern Nano ZS, respectively. To get desired 
particle size separately solubilized 10mg of weighed quantity 
of freeze-dried nanoparticle of each formulation in 10ml of 
phosphate buffer solution pH 6.8 and subjected to particle 
size analyzer at 25±1°C, an electric field of 150mv with a 90° 
angel of scattering. All measurements were taken in 
triplicate (n=3) 
Transmission electron microscopy (TEM) 
Geometry, particle shape and surface topography of 
optimizedTEL-SLN18 formulation were investigated by 
transmission electron microscopy (TEM, FTI Tecnai F20). 
Briefly, a dispersion of telmisartan loaded nanoparticle 
formulation was preparedin phosphate buffer solution pH 
6.8 and drop of the sample was soaked onto a carbon-coated 
copper grid, and the grid was subjected to air-dried at room 
temperature. The air-dried grid was loaded into a 
microscope which was already maintained at 80 kV and 
observed. The images were captured and analyzed by 
software. 
Fourier transforms-infrared (FT-IR) spectroscopy 
FT-IR analysis was carried out to allocution the existence of 
any interaction between the functional group of drug and 
excipients. FTIR spectrum of pure drug telmisartan, physical 
mixture of drug and excipients, blank lipid nanoparticle and 
tailored formulation TEL-SLN18 were recorded by scanning 
in a range of 400-4000 cm-1 at a resolution of 4 cm-1. Each 
sample was prepared into KBR disc by employing 
hydrostatic press at a force of 40 psi. 
Powder X-ray diffraction (PXRD) pattern 
To investigate the polymorphic state of the drug into nano-
size range lipid matrix powder XRD analysis was carried out 
using powder x-ray diffractometer(Ultima-4, Rigaku 
Company, Japan)with Ni-filtered, Cu K-radiation, a voltage of 
60 kV and a current of 50 mA. The PXRD diffract gram of 
pure drug telmisartan, physical mixture of drug and 
excipients, blank lipid nanoparticle and TEL-SLN18 were 
recorded by scanning over a rangeof5 to 50° diffraction angel 
at a rate of 1°/min. 
In vitro drug release study 
In vitro drug release study was performed to study the 
release pattern of telmisartan from our tailored formulation 
and compared with the release pattern of the market 
preparation. It was carried out by using dialysis diffusion 
tubing technique1 employing a dialysis membrane with 
molecular weight 12-14 KDA in fresh phosphate buffer 
solution pH 6.8 An accurately weighed quantity of tailored 
formulation equivalent to 40mg of telmisartan and market 
preparation was resuspended separately into 5ml of 
phosphate buffer 6.8 pH and filled in dialysis tubing. The 
dialysis tube was immersed into 900 ml of phosphate buffer 
6.8 pH (without serum), maintained at 37° and stirred at 
constant speed 100rpm. At predetermined specified time 
interval 5ml of dissolution medium was withdrawal up to 
26hr from receiver compartment and simultaneously 
replenished with the same amount of media 6.8pH (without 
serum) to simulate sink condition. The aliquots were 
appropriately dilute with media and concentration of drug in 
each withdrawal aliquots were determined using UV 
spectrophotometer at 298nm. 
In vitro drug release of tailored formulation was fitted into 
various mathematical model including zero order, first order, 
Higuchi and korsmeyer-pepaas model to determined 
mechanism to characterize of drug release pattern from 
tailored formulation. Regression value of regression 
coefficient, intercept and n (exponent) was calculated for 
each model to determine the best fit model. 
Cell cytotoxicity study 
A standard colorimetric MTT assay, as an in vitro cytotoxicity 
assay, was employed to investigatetheeffect of market 
preparation of telmisartan and TEL-SLN18over the cell 
viability using 96 well microtiter plates. The principal of the 
assay is based on the metabolic conversion of MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide) into 
a formazan dye by the mitochondrial enzyme succinate 
dehydrogenase of the viable cells and that formazan dye 
further absorbs light at 550nm. The cervical cancer cell line 
was seeded at a density of 5×103/well in 200µL of serum 
DMEM medium in (3-[4,5-dimethylthiazol-2-yl]-
2,5diphenyltetrazolium bromide).  After an incubation 
period of 24hr medium is replaced with serum-free DMEM 
and subsequently seeded cells were exposed to a gradient 
concentration of telmisartan, telmisartan loaded 
nanostructure solid lipid particle equivalent to 20-100µM for 
72hr. At the end of the predetermined incubation period 
20µL MTT dye (mg/ml) was added to each well and each 
plate was incubated for a period of 4 hr at 37°C. Following 
cell lysis, the supernatant was decanted and consequently 
obtained formazan crystal was dissolved in 100µL of DMSO. 
The absorbance of the mixture was measured at 5670nm and 
630nm as a reference wavelength by employing ELISA 
reader. All steps of the Study were carried out in triplicates 
RESULTS AND DISCUSSION 
Preparation of telmisartan loaded nanostructure lipid 
solid lipid particles 
Solvent diffusion method was successfully employed for the 
preparation of TEL-SLN. An organic lipid phase containing 
telmisartan was dispersed into an aqueous surfactant 
solution and subsequently, telmisartan loaded nano-size 
range lipid emulsion droplets was formed. Heating step 
triggered thediffusion of organic solvents consequently 
increases the concentration of lipid inside the droplets. Upon 
cooling, solidification of lipid emulsion droplets and 
absorption of poloxamer around the surface of spherical lipid 
particles were accomplished simultaneously. 
Optimization and validation using box behnken design 
To obtained stable telmisartan loaded nanoformulation with 
low particle size and high drug encapsulation efficiency, 
optimization and validation of various process and 
formulation parameters was required Before optimization 
process, preliminary screening was accomplished by 
conducting various trails to determine most anticipated 
formulation and process independent variables by 
evaluating their effect over the physicochemical properties 
of drug-loaded nano-size range solid lipid particulates. Based 
on a result of preliminary screening, three most critical 
independent variables including percentage lipid to drug 
ratio (X1), amount of surfactant (X2)and stirring rpm (X3) 
with three levels (low, middle and high)  were selected as 
illustrated in table no 1and evaluated their effect on the 
physicochemical property of drug loaded solid lipid 
nanoparticle. For three-factor and three levels, box 
behnkendesign offer advantage in terms of no. of run among 
all types of design, because it was yielding only 17 runs in 
comparison of central composite design and factorial design, 
were yielding high numbers of the run. Based on experiment 
efficiency and no. of run box behnken design was selected for 
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optimization and validation of telmisartan loaded solid lipid 
nanoparticle.  
On applying of box behnken design with three factors and 
three levels, 17differentformulations were yieldedand 
prepared with Response of particle size (Y1) and percentage 
drug entrapment (Y2) for 17 formulations were evaluated as 
summarized in Table 2.Data of all 17 formulations were 
simultaneously fitted into box behnkendesign10 to obtain 
predicted value of both response. For each response Y1 and 
Y2, statistical parameters are including mathematical model 
analysis, adjusted R2 and predicted R2 value was determined 
and summarized in Table 3 respectively. It was evident that 
all three independent variables have individual and 
interactive influence on the responses (Baig et al. 2016). 
Significance of each statistical parameter on responsewas 
depending on the p value asdetermined by employing 
ANOVA. Table 4-5 summarize the effect of each as well as a p 
value of all terms for all the response.  Variables associated 
with p value <0.05 were considered to be significant 
only.Reckoning of the statistical parameter for each response 
attributedquadratic mode is the best fit model for each 
response as having high R2 value for both Y1 and Y2 
response, among all other mathematical models. Higher non-
significant value of Lack of fit measures the suitability of the 
model for an experimental result.Positive and negative sign 
before each coefficient in software generated quadratic 
polynomial equation bearing individual and combined factor 
revealedboosting or castrating impact of variableson the 
response respectively. Interaction and quadratic terms 
described the non-linearity between factors and responses. 
The intercept represented the mean of the response.  
Perturbation graph were presenting to explain effect of each 
factor on response in better way. If design having more than 
two factor then perturbation plot has been a best 
diagrammatic tool to identify the most influencing factor end 
their effect on response. These plot demonstrated sensitivity 
of each response toward particle factor, while all other factor 
remain constant at response point by changing in curvature 
of graph.   
Three dimensional plotswere identified as a useful 
diagrammatic tool to study the interaction and quadratic 
effect of two predetermined variables while retaining the 
third factor as a constant at one time on the observed 
response of particle size, polydispersity index, and drug 
encapsulation efficiency. 
Effect on particle size 
Particle size is the most vital parameter that governs the 
therapeutic efficacy and stability of drug loaded solid lipid 
nanoparticles in situ biological milieu. Hence the aim of this 
study experiment was to optimized formulation with 
minimum particle size. In order to determine the established 
relationship between all selected independent variable and 
particle size of telmisartan loaded solid lipid nanoparticles 
several different mathematical models including linear, 2FI, 
Quadratic and cubic were fitted to obtain the best fit model.10 
Selection of model is depending on the value of regression 
coefficient as summarized in Table 3 was found maximum 
0.998313 forthe quadratic model. According to ANOVA 
report (Table 4) F value and the p value of model was found 
to be 460.22 and <0.0001 implies that the quadratic model 
was the best fit model while the F value of lack of fit value of 
0.13 also confirm the significance of quadratic model relative 
to the pure error. Furthermore,drug to lipid ratio (X1), 
concentration of surfactant (X2),  stirring rpm (X3), 
X1X2&X2X3 (interactive term), X12&X32 are significant 
model terms because they all were having p value <0.0001 
and model had good agreement between "Pred R-Squared" 
of 0.9951 and "Adj R-Squared" of 0.9961. The particle size of 
all prepared formulation was found in a range of 68.14±1.15 
to 132.1±2.19 nm with average particle size 91.910nm, 
respectively.Influence of all selected independent variable on 
the particle size was determined by employing quadratic 
equation in term of coded factor as described in equation no 
1. 
Particle size (Y1) = 80.76 + 22.78 X1 -5.98X2 -6.75 X3 -6.67 
X1X2 + 0.81 X1 X3 –2.21X2 X3 +10.09 X12+ 1.09 X22+ 12.52 
X32(1) 
Equation no 1 clearly showedparticle size was significantly 
increased synergistically by increasing drug to lipid ratio 
(X1), X12&X32 and decrease in antagonist way by increasing 
concentration of surfactant (X2),  Stirring rpm (X3), 
X1X2&X2X3 (interactive term). The large value of coefficient 
(22.91) depicted that particle size largely influenced by the 
lipid to drug ratio in comparison to a low coeeficent value of 
surfactant (-5.98) and stirring rpm (-6.75). The reasons 
could probably be that higher drug to lipid ratio would 
enhance the viscosity of dispersion which makes difficult to 
disrupt emulsion droplets, and reduced the emulsification 
capacity of surfactant leading to enhance coalescence of 
particles, yielding particle with large size. Similarly, the 
amount of surfactant had a contrast effect on particle size. 
Positive gradient concentration of surfactant produces 
uniform and stable nanoparticles by reducing the interfacial 
tension between lipid and external phase. 
Despite the amount of surfactant, stirring speed also had 
negative effect on particle size. Positive increment of stirring 
rpm would increase kinetic energyallowingparticles to 
collide with the greater force,resulting in particles with small 
size. Figure1Aas showed that independent variable X1(lipid 
to drug ratio) displayed more curvature in graph among all 
three factors, illustrated more pronounced effect on the 
particle size than the variable X3 (stirring rpm) and  X2 
(concentration of surfactant ).  
Interaction between the variables X1X2 and X2X3 had 
negative effects on the particle size and X1X3 interactive 
term had a positive effect on particle size. This interaction 
can be utilized to tailor particle size according to the values 
of factors. 3D surface response graph as shown in figure 
no.1B describing that drug to lipid ration had a positive effect 
while the concentration of surfactant and stirring rpm had a 
negative effect on the particle size and in the same way 
interactive and quadratic terms X1X2, X1X3, X2X3, X12, X22, 
and X32alsohad an influence on the particle size of drug 
loaded solid lipid nanoparticle. 
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Figure 1: Effect of process variables during preparation of telmisartan loaded solid lipid nanoparticles 
Effect on percentage drug entrapment 
Parentage drug encapsulation for all prepared formulations 
was found to be in the range of 62.21±0.377 to 86.04±0.15 
with a mean value of 77.399. All the data were fitted in a 
different mathematical model and evaluated for the 
response of percentage drug encapsulation efficiency. 
According to ANOVA report model, F value (307.50) implied 
that the quadratic model is significant with a p value 
<0.0001 and lack of fit value 0.19 as illustrated in Table 
5.There was a significant correlation between the Pred R-
Squared" of 0.9916 and Adj R-Squared" of 0.9942 Despite 
the quadratic model, independent variable like  X1, X2, X3, 
interactive terms (X1X2, X1X3 &X2X3) and quadratic terms 
(X12&X22&X32) are also significant with a p value less 
than<0.005.  
The quadratic polynomial equation for the response% drug 
encapsulation in term of coded factor is as follow: 
Percentage drug encapsulation efficiency (Y2) = +83.69 + 
9.23 X1 -0.85X2 -0.51 X3 -1.23X1X2 + 1.53X1 X3 –3.46X2 X3 
-5.65 X12-3.33 X22-4.38X32…………………….(2) 
In quadratic equation 2 positive and negative sign before 
coefficient indicates the synergistic and antagonist effect of 
variables on response encapsulation efficiency of drug 
loaded solid lipid nanoparticle while the magnitude of each 
coefficient suggested the contribution of each factor to the 
response. Quantitativeestimations of the model illustrated 
that drug to lipid ration displayed significant influence on 
percentage drug encapsulation efficient with F value 
1806.55 and p value <0.0001.By increasing the internal 
phase, more amount of lipid was available to solubilize the 
drug and decreased the partition of the drug into the 
external phase. Moreover, higher lipid enhanced the 
viscosity of the dispersion that would offer résistance to the 
diffusion of drug molecule into the aqueous phase resulting 
in higher drug entrapment efficiency. 
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Figure 2: Study of independent variables 
Perturbation graph 2A showed that independent variable 
X1(lipid to drug ratio) displayed more curvature in graph 
among all three factors, illustrated more pronounced effect 
on the percentage drug encapsulation than the variable X3 
(stirring rpm) and  X2 (concentration of surfactant ).  The 
physicochemical property of drug also governed the drug 
encapsulation efficiency of the drug into lipid 
nanoparticleslike telmisartan was hydrophobic in nature 
having more tendencies 
to solubilize into lipid thereby yielding higher drug 
encapsulation efficiency.As lipid to drug ratioincreased 
encapsulation of drug into lipid matrix of solid lipid 
nanoparticles would simultaneously enhance up to a 
maximum value and then decreased in an umbrella shape 
pattern depend on the affinity of drug towards the lipid 
stearic acid as depicted in 3D surface response graph as 
shown in Figure 2B.In contrast to the lipid to drug ratio, the 
concentration of surfactant and stirring rpm were inversely 
proportional to percentage drug encapsulation. High 
surfactant concentration in the external phase might favor 
the partition of the drug from the internal phase to external 
aqueous dispersing medium,leadingsolubilization of drug 
into an aqueous solution and decreased encapsulation 
efficiency. Similarly increasing in stirring rpm resulted in 
more expulsion of the drug from lipid nanoparticle then 
reduced the drug entrapment efficiency. Effect of both 
independentvariables was not prominent because 
telmisartan is a hydrophobic and strongly associated with 
lipid molecule resulting in encapsulation of drug in lipid 
core. 
Optimization and validation  
Effect of all independent variable on both response particle 
size and percentage drug encapsulation was demonstrated 
by employing quadratic polynomial equation was further 
optimized and validatedto obtain stable formulation with 
minimum particle size and maximum drug encapsulation 
efficiency.The optimal value predicted for independent 
variables including lipid to drug ration, concentration of 
surfactant and stirring rpm were 3.02:1, 1.09% w/v and 
779.43 with desirability 0.856. 18 The value of desirability 
illustrated the closeness of value toward the target value and 
varied from 0 to 1depending on the desired and non-desired 
situation of responsepredicted value for response including 
particle size and percentage drug encapsulation efficiency 
was found to be 79.6001nm and 83.4651, respectively. To 
confirm predicated formula, validation was carried out by 
preparing a new batch of telmisartan loaded solid lipid 
nanoparticle and determine the magnitude of error between 
the observed experimental value and predicted value.The 
observed experiment value for particle size and percentage 
drug encapsulation efficiency was found to be 78.90± 1.8 nm 
and 82.88± 2.4 were in reasonable agreement with a 
predicted value suggesting the selected box Behnken 
optimization design were truthful and trustworthy for 
tailored telmisartan loaded solid lipid nanoformulation. 
Particle size polydispersity index and Zeta Potential 
Size of particle plays a vital role in the therapeutic efficacy of 
nanoformulation because of nanoparticle with particle size 
<100 can easily lymphatic system through peyer patches 
resulting in enhanced drug delivery via oral administration. 
The particle size of optimized formulation was found to be 
78.90±1.8as given in table no.9 and figure no. 
3Arespectively. Nanoparticle with particle size <200nm was 
reported to be easily escaped through reticuloendothelial 
system recognition; therefore, it can release the drug in a 
sustained manner over a long period of time in systemic 
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circulation.Membrane wrapping process was known to be 
responsible for uptake of nanoparticle depending on size 
(30-50nm). It is based on the principle that small particle 
with size range 30-50nm engender free energy to uphold the 
internalization while particle with size range >50nm did no 
generated sufficient energy to initiate this membrane 
wrapping process.Polydispersity index defined the 
uniformity of particle into dispersion and varied from 0 to 1. 
Low value of PDI indicated uniform homology between 
particles. Table 6 described PDI value for all formulations 
was found to be in the range of 0.09±0.21 to0.152±0.61. In 
addition, PDI value for the optimized formulation was 
observed to be 0.119±0.879respectively, indicated that 
particle was uniform in prepared solid lipid nanoparticles.
 Zeta potential attributed the magnitude of charge 
present on the surface of the nanoparticle and plays a 
significant role in illustrating stability and in vivo fate 
aqueous dispersion of nanoparticle. The ideal range of zeta 
potential was reported to be +30mv to -30mv to obtain a 
stable aqueous dispersion. The reason could probably the 
existence of attractive and repulsive force between particles 
which is responsible for agglomeration or deagglomeration 
of particles in aqueous dispersion. Despite the stability of 
aqueous dispersion, zeta potential also determines the in 
vivo pharmacokinetic behavior, circulation, and immune 
response. Zeta potential of tailored optimized formulation 
was found to be 38.19±1.98,respectively as shown in Figure 
3A. The negative value of zeta potential was due to 
functional group COO- of stearic acid. 
 
 
Figure 3: Particle size, zeta-potential and transmission electron microscopy of telmisartan loaded solid lipid 
nanoparticles 
TEM analysis 
The surface architecture of telmisartan loaded lipid 
nanoparticle depicted in Figure 3B expressing that prepared 
nanoparticle were spherical, discrete, uniform in shape and 
free form any surface deformability 33 with a size range 20-
50nm.  
Percentage drug loading of telmisartan on lipid 
nanoparticle 
Percentage drug encapsulation for all TEL-SLNswere found 
to be in the range of 6.24±0.032% to 8.60±0.015% as shown 
in table no.6. Furthermore, for final optimized formulation it 
was measured to be 8.34±0.025%. 
FTIR spectrum analysis 
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FTIR spectrum of telmisartan, physical mixture of 
telmisartan, poloxamer 188 and stearic acid in equimolar 
ratio, blank lipid nanoparticle and optimized TEL-SLN18 was 
apprehended to probe the chemical incompatibility and 
existence of chemical bond between lipid and drug 
characteristics stretching and bending vibration in term of 
wavenumber of drug, lipid, physical mixture, blank lipid 
nanoparticle, and drug-loaded lipid nanoparticle was 
depicted in figure no. 4. FTIR spectrum of pure drug 
telmisartan showed the characteristic peaks at wavenumber 
of 3350.42 cm-1, 2970.32 cm-1, 1696.04 cm-1, 1377.52 cm-1 
and 746.32 cm-1 corresponding to the   aromatic C-H stretch, 
aliphatic C-H stretch, carboxylic acid, OH bending and C-O 
stretching of carboxylic acid, OH bending and C-O stretching 
of carboxylic acid, respectively. 
FTIR spectrum of TEL-SLN18 showed a slight shift in 
wavenumber at 2915.83 cm-1 (aliphatic C-H stretch) and 
2849.42 cm-1 for CH3/CH2 groups and 1697.32 cm-1 for -
OC=O concerning original peaks of drug 
telmisartan.However, in comparison to drug lipid 
nanoparticle, the physical mixture did not display a shift in 
wavenumber of theses peaks in both components (Figure 4). 
Therefore FTIR spectrum analysis confirmed the absence of 
any chemical incompatibility between components as well as 
evidence that drug was persisted with their chemical 
functional groups and their chemical stability was not 
affected by lipid matrix during encapsulation. 
 
 
Figure 4: FT-IR spectrum of (A) telmisartan (B) blank solid lipid nanoparticles (C) physical mixture and (D) telmisartan loaded 
solid lipid nanoparticles 
PXRD Analysis 
Polymorphic state of drug and lipid in solid lipid 
nanoparticle was elected by comparing the diffractogram of 
pure drug telmisartan, physical mixture, blank lipid 
nanoparticle, and TEL-SLN18 as shown in Figure 5, 
respectively. The XRD pattern of pure drug telmisartan and 
physical mixture displayed sharp and intense characteristic 
peaks indicating the crystalline state of telmisartan in bulk 
form and physical mixture as well as implying that there was 
no incompatibility between drug and lipid.However, the 
characteristic peak of telmisartan was disappeared in PXRD 
pattern of telmisartan loaded solid lipid nanoparticle 
provides support to inference the telmisartan was well 
molecularly dispersed and encapsulated in lipid matrix of 
solid lipid nanoparticle and stabilized amorphous state 
(Figure 5). Moreover, in telmisartan loaded solid lipid 
nanoparticleprincipal peaks of stearic acid was not 
completely absent, rather appeared with reduced intensity. 
The reason may elucidate that incorporation of the drug 
between crystal lattice of lipid, leading to changes in the 
lattice structure of lipid in solid lipid nanoparticle. 
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Figure 5: XRD pattern of (A) telmisartan (B) blank solid lipid nanoparticles (C) physical mixture and (D) telmisartan loaded 
solid lipid nanoparticles 
In vitro drug release 
In vitro drug release study of TEL-SLN18and market 
preparation Telvas 40 was carried out by employing dialysis 
tubing method with a semipermeable dialysis membrane. 
Percentage drug release for telmisartan loaded solid lipid 
nanoparticle and market preparation was found to be in the 
range of 6.81±1.73% to 20.39±0.85% and 9.11±2.95% to 
78.40±3.17% as can be clearly visualized in Figure 6,TEL-
SLN18 showed drug release in the biphasic pattern including 
burst release 11.65±3.03%of telmisartan at initial time 
interval within 1hr, following by releasing 77.84±2.83%of 
the drug in a sustained manner up to 24hr. 24.  
 
 
Figure 6: In vitro drug release from telmisartan and telmisartan loaded solid lipid nanoparticles 
The initial burst can be attributed to the small size, large 
surface area and unentrapped drug adsorbed around the 
surface of tailored formulation.Whereas, in later stage slow 
release of telmisartan from solid lipid nanoparticle provides 
support to the assumption that drug was homogenously 
encapsulated into the inner core of solid material of 
formulation and diffuse out through both diffusion and 
dissolution mechanism. In contrast to solid lipid 
nanoparticle, marketed preparation displayed very less 
release of drug 20.39±0.85%within 24 hrin comparison to 
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sustained release of telmisartan loaded solid lipid 
nanoparticle. 
In order to suggest a mechanism of drug release from 
tailored formulation experimental data was fitted into 
different mathematical modal and check the goodness of fit 
of the model by comparing the value of statistical parameters 
including regression coefficient, intercept and release 
exponent as depicted in Table 7. The regression coefficient 
value was found to be maximum for Korsmeyer-Peppas 
model 0.9181 followed by Higuchi 0.8799 and first-order 
0.848, respectively.The release exponent value 0.6485. 
Indicated that the release of telmisartan from tailored 
formulation followed nonfickian diffusion, indicating the 
release of molecularly encapsulated drug was controlled by 
diffusion and erosionof the core of solid lipid of the tailored 
formulation. Similar release kinetic for drug-loaded solid 
lipid nanoparticle was reported in previous literature. 
In vitro anti-cancer cell line study 
 
 
Figure 7: In vitro cytotoxicity assay of telmisartan, telmisartan loaded solid lipid nanoparticles and blank solid lipid 
nanoparticles against human cervical cancer cells, HeLa 
To determine the toxic effect of tailored nanoformulation and market preparation over cancer cells, in vitro cancer cell line 
cytotoxicity was carried out using MTT assay against HeLa cells (Human cervical cancer cell line) and measured IC50 value of 
each formulation. In this case, placebo lipid nanoparticle was used as control. IC50 value defined as a minimum concentration of 
formulation required to kill 50% of cells. Figure 7 described the IC50 value of telmisartan loaded lipid nanoparticle and market 
preparation, indicated telmisartan loaded solid lipid nanoparticle expressed lower IC50 value of 30.28μM with significant 
anticancer activity against HeLa cancer cell line in comparison to higher IC50 value 58.69μM of market preparation. Moreover, 
placebo solid lipid nanoparticles did not show anticancer activity against HeLa cancer cell line.The higher cell cytotoxicity and 
low IC50 value was evident to the higher uptake of tailored nanoformulation by cancer cell line. 
Table 1: Independent and dependent variables with their levels in Box-Behnken design for the development of 
telmisartan loaded solid lipid nanoparticle 
Independent variables 
Factor Name Units Low Actual High Actual Mean 
Low (-1) High (1) Mean (0) 
X1 Lipid to Drug Ratio  2:1 4:1 3:1 
X2 Surfactant (Poloxamer 1)88 (%w/v) 0.5 1.5 1 
X3 Stirring speed RPM 500 1000 750 
Dependent variables 
Particle size (nm) 
Percentage drug entrapment 
 
Table 2: Observed value and predicted value of all response in Box-Behnken design for the formulation of telmisartan 
loaded solid lipid nanoparticle (n=3) 
Formulation 
code 
Independent Variables Dependent Variables 
Factor 1(X1) 
Lipid to Drug 
Factor 2 (X2) 
Surfactant 
Factor 3 (X3) 
Stirring speed 
Particle size (Y1) Percentage of drug entrapment 
(Y2) 
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Sharmaet al                         Journal of Drug Delivery & Therapeutics. 2019; 9(2):612-624 
ISSN: 2250-1177                                                                  [622] CODEN (USA): JDDTAO 
Ratio 
 
(%w/v) RPM Observed 
Value 
Predicted 
value 
Observed 
Value 
Predicted 
value 
S1 3 1 750 81.1 80.756 84.46 83.688 
S2 3 1.5 500 97.01 97.3425 79.19 79.1025 
S3 3 1 750 82.09 80.756 83.15 83.688 
S4 4 0.5 750 127 127.36625 86.04 86.0075 
S5 2 1 1000 73.02 73.03125 62.21 62.39 
S6 2 1 500 88.11 88.14375 66.42 66.475 
S7 2 0.5 750 68.14 68.46125 65.37 65.1025 
S8 2 1.5 750 70.21 69.84375 65.82 65.8525 
S9 3 1.5 1000 79.08 79.435 71.36 71.1475 
S10 3 0.5 500 105.24 104.885 73.67 73.8825 
S11 3 1 750 82.3 80.756 83.1 83.688 
S12 3 0.5 1000 96.14 95.8075 79.69 79.7775 
S13 3 1 750 79.07 80.756 84.58 83.688 
S14 4 1 500 132.1 132.08875 82.05 81.87 
S15 3 1 750 79.22 80.756 83.15 83.688 
S16 4 1.5 750 102.39 102.06875 81.58 81.8475 
S17 4 1 1000 120.25 120.21625 83.95 83.895 
 
Table 3: Summary of the value of regression coefficient analysis of the models for responses Y1 and Y2 of telmisartan 
loaded solid lipid nanoparticle 
Response 1 (Y1) Particle size  
Model R-Squared Adjusted 
R-Squared 
Predicted 
R-Squared 
Std. 
Dev. 
CV % Remark 
Linear 0.776528 0.724957535 0.630693311 10.31075251 11.22  
2FI 0.808879 0.694206173 0.427439223 10.87188484 11.83  
Quadratic 0.998313 0.996143656 0.995145191 1.220895163 1.33 Suggested 
Cubic 0.998467 0.993866085  1.539782452 1.68  
       
Response 2 (Y2) Percentage drug entrapment 
Model  R-Squared Adjusted 
R-Squared 
Predicted 
R-Squared 
Std. 
Dev. 
CV %  
Linear 0.658695 0.579932085 0.470061392 5.239448328 6.77  
2FI 0.719248 0.550797399 0.324541767 5.418099013 7  
Quadratic 0.997477 0.994233373 0.991616042 0.613884587 0.79 Suggested 
Cubic 0.997785 0.991139067  0.760966491 0.98  
 
Table 4: Summary of the value of Analysis of the variance of the calculated model and independent variables for 
response particle size Y1 of telmisartan loaded solid lipid nanoparticles 
Source Sum of 
Squares 
df Mean 
Square 
F 
Value 
p-value 
Prob> F 
 
Model 6174.014105 9 686.0015672 460.2230448 < 0.0001 significant 
X1-Lipid to Drug Ratio 4152.33845 1 4152.33845 2785.71061 < 0.0001  
X2-Surfactant 285.9636125 1 285.9636125 191.8465653 < 0.0001  
X3-Stirring speed 364.0951125 1 364.0951125 244.2632339 < 0.0001  
X1X2 177.9556 1 177.9556 119.3864154 < 0.0001  
X1X3 2.6244 1 2.6244 1.76065102 0.2262  
X2X3 19.492225 1 19.492225 13.07689598 0.0086  
X12 428.7294129 1 428.7294129 287.6249344 < 0.0001  
X22 4.986476053 1 4.986476053 3.345314794 0.1101  
X32 660.3443813 1 660.3443813 443.010215 < 0.0001  
Residual 10.434095 7 1.490585    
Lack of Fit 0.950375 3 0.316791667 0.133614939 0.9350 not 
significant 
 
Table 5: Summary of the value of Analysis of the variance of the calculated model for response and independent 
variables for response percentage drug encapsulation Y2 of telmisartan loaded solid lipid nanoparticles 
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Source Sum of 
Squares 
df Mean 
Square 
F 
Value 
p-value 
Prob > F 
 
Model 1042.977 9 115.8862793 307.5095169 < 0.0001 significant 
X1-Lipid to Drug Ratio 680.805 1 680.805 1806.547055 < 0.0001  
X2-Surfactant 5.81405 1 5.81405 15.42784631 0.0057  
X3-Stirring speed 2.1218 1 2.1218 5.630292876 0.0494  
X1X2 6.027025 1 6.027025 15.99298516 0.0052  
X1X3 9.333025 1 9.333025 24.76560664 0.0016  
X2X3 47.95563 1 47.955625 127.2524337 < 0.0001  
X12 134.5414 1 134.5414003 357.0117294 < 0.0001  
X23 46.76725 1 46.76725289 124.0990342 < 0.0001  
X32 80.69345 1 80.69345289 214.1237501 < 0.0001  
Residual 2.63798 7 0.376854286    
Lack of Fit 0.3217 3 0.107233333 0.185181987 0.9013 not 
significant 
 
Table 6: Percentage drug loading and PDI of all telmisartan loaded solid lipid nanoparticles (n=3) 
Formulation code Percentage of drug Loading PDI 
S1 8.47±0.009 0.118±0.23 
S2 7.96±0.013 0.11±0.59 
S3 8.31±0.009 0.115±0.64 
S4 8.60±0.015 0.19±0.39 
S5 6.24±0.032 0.09±0.21 
S6 6.62±0.018 0.105±0.44 
S7 6.53±0.013 0.135±0.57 
S8 6.54±0.034 0.11±0.75 
S9 7.15±0.023 0.113±0.53 
S10 7.36±0.005 0.145±0.6 
S11 8.31±0.151 0.111±0.36 
S12 7.91±0.014 0.151±0.42 
S13 8.45±0.016 0.116±0.08 
S14 8.24±0.025 0.134±0.11 
S15 8.31±0.009 0.113±0.96 
S16 8.10±0.036 0.145±0.41 
S17 8.33±0.016 0.152±0.61 
 
Table 7: Value of regression coefficient for different Mathematical model used for evaluation of drug release kinetic of 
telmisartan loaded solid lipid nanoparticle 
Formulation 
Name 
Zero-order First-order Higuchi Peppas 
R2 K0 R2 K0 R2 K0 R2 K0 
SL18 Formulation  0.783 2.99 0.848 -0.027 0.8799 19.13 0.9181 0.6458 
CONCLUSION In conclusion, we have successfully prepared and scaled up 
the solid lipid nanoparticles of telmisartan for drug delivery 
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to cervical cancer cells.Further, optimization techniques help 
to achieve a good yield of nanoparticles with minimum use 
of organic solvents. The optimized formulation exhibited low 
IC50 value as compared to telmisartan. Hence, we could 
predict that telmisartan loaded solid lipid nanoparticles 
would be a potential drug delivery system.  
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